Evidence dossiers on existing drugs for rare diseases with no treatment
TL;DR Orphanwell searches the published biology and clinical literature for drugs already sold in India that might help a specific rare disease, then writes a ranked, referenced dossier. Patient groups, government Centres of Excellence and Indian drug makers pay per disease. It produces hypotheses for doctors and researchers to test, never treatment advice.
Most rare diseases have no approved drug anywhere. Every Cure, a US nonprofit, counts about 18,000 recognised diseases and approved treatments for roughly 4,000[1]. In India the gap is wider, because imported orphan drugs cost a bomb.
The national rare disease policy offers up to ₹50 lakh per patient, yet only about 1,800 patients had received treatment support by May 2026[2]. Of ₹200 Cr earmarked for rare diseases in earlier years, about ₹7 Cr had been spent by 2023[3].
Families organise themselves through groups such as ORDI, which lists 8,250 associated patients[4], but they rarely have the scientific staff to judge which existing medicine might be worth a trial.
What it does, in regulatory terms: research evidence synthesis, not treatment advice or a drug claim. Dossiers go to clinicians, researchers and companies. Any use in patients is the treating doctor's call, and any study must follow trial rules, including CTRI registration, which has been mandatory since 2009[5].
For each disease, Orphanwell maps the known mechanism, then mines literature, gene-drug databases and case reports for drugs that act on the same pathway. A medical scientist reviews every candidate and grades the evidence. The output is a dossier of five to ten candidates, each with its Indian approval status, typical cost and the experiment that would test it fastest.
The seed wanted AI-driven network pharmacology to discover rare disease drugs, and I reframed it. Discovering new molecules takes years and large capital, and few Indian buyers fund that. Repurposing medicines already approved here is cheaper, and the national policy itself encourages it[3].
Patients and families benefit. The payers are patient foundations funding research, Centres of Excellence writing grant proposals, and Indian generic makers looking for a new use for an existing molecule. I found no public price for repurposing dossiers in India, so a fixed fee per disease has to be tested in early deals.
The Health Ministry has stepped up its rare disease push - Centres of Excellence went from 8 to 15, and six repurposed drugs have been identified with clinical work under way, according to a May 2026 report[2]. Language models now make first-pass literature screening cheap, which leaves expert review as the main cost.
There's no public figure for Indian spending on rare disease repurposing research. One analysis found 76% of US-approved repurposed orphan drugs are fully or partly available in India, and 61% have CDSCO approval[3]. So a lot of candidate molecules are already sitting on Indian shelves. Size the market bottom-up from patient groups and Centres of Excellence.
Every Cure in the US uses AI to rank existing drugs against diseases and pushes the best through to trials as a nonprofit[1]. Healx in the UK describes itself as an AI-native rare disease drug company[6]. In India, ORDI runs advocacy, helplines and trial updates[4].
I found no service that produces disease-by-disease repurposing dossiers for Indian buyers. That's the gap.
| Difficulty | Moderate (41/100) |
| Starting capital | ₹35–65 L |
| Time to launch | 4–6 months |
The pipeline is buildable with public databases. Credibility and payment are the hard parts. Clinicians will discount a dossier from an unknown firm, so expert reviewers with rare disease standing matter more than the model. And patient groups often have very little money.
No licence to write dossiers, but clinical trial and drug-promotion rules apply to how they're used.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
AI generates hypotheses here, not advice. Never let a model's ranking reach a patient as a treatment suggestion, and have a medical scientist check every citation.
Want to work out the AI layer for Orphanwell? Talk to Yash →
This is a good one for a pharmacologist or rare disease researcher who writes carefully and wants a lean services business. If you want a venture-scale drug pipeline from day one then this isn't it. First prove that one Centre of Excellence or drug maker will pay for a dossier and act on one candidate.
Plan for roughly ₹35–65 L, mostly on a small team of scientists and access to literature and databases.
No licence for the dossiers themselves. Any study in patients needs ethics approval and CTRI registration, and you shouldn't market dossiers to patients as treatment.
Yes, rare disease groups everywhere need this. You'd check approvals and prices for that market and follow its trial and drug-promotion rules.
The free Orphanwell validation kit has the line-by-line capital breakdown, the effort scoring, the trial and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for patient groups and clinicians, and 5 assumptions to test. Download the kit →
Thinking about building Orphanwell or something close to it? The make-or-break bit is finding a buyer with both budget and a clinician ready to test what you find, and I can help you work out where that buyer sits. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.